

```

      18
      ↓
1  MKCLLYLAFL FIGVNCKFTI VFPHNQKGNW KNVPSNYHYC PSSSDLNWHN
      51  55
      ↓  ↓
51 DLIGTAIQVK MPKSHKAIQA DGWMCHASKW VTTCDFRWYG PKYITQSIRS

101 FTSPVEQCKE SIEQTKQGTW LNPGFPPQSC GYATVTDAEA VIVQVTPHHV
      191 196
      ↓  ↓
151 LVDEYTGWV DSQFINGKCS NYICPTVHNS TTWHS DYKVK GLCDSNLISM
      217
      ↓
201 DITFFSEDGE LSSLGKEGTG FRSNYFAYET GGKACKMQYC KHWGVRLPSG

251 VWFEMADKDL FAAARFPECP EGSSISAPSQ TSVDVSLIQD VERILDYSLC

301 QETWSKIRAG LPISPVDLSY LAPKNPGTGP AFTIINGTLK YFETRYIRVD
      368
      ↓
351 IAAPILSRMV GMISGTTTER ELWDDWAPYE DVEIGPNGVL RTSSGYKFPL

401 YMIGHGMLDS DLHLSSKAQV FEHPHIQDAA SQLPDDESLE FGD TGLSKNP

451 IELVEGWFS WKSSIASFFF IIGLIIGLFL VLRVGIHL CI KLKHTKKRQI

501 YTDIEMNRLG K*

```

Figure S1. Protein sequence of VSV-G. The possible insertion sites are colored in blue.




Figure S2. FACS gating strategy for T cell analysis.





















	d7	d14	d21	d90
Untreated				
pTOP				
ICBs Non-responder				
ICBs Responder				
Combination Non-responder				
Combination Responder				

Figure S3. Follow-up of tumoral growth by MRI. A representative mouse was selected for each group.




Figure S4. Rechallenge of long-term survivors. (A) Comparison of tumor volumes between the three groups. Values are mean \pm SEM; $n = 3-6$. (B) Evolution of tumor volumes of each mouse from the untreated group; $n = 6$. (C) Survival curves following rechallenge of long-term survivors from the group treated with ICBs and with the combination; $n = 3-6$. Statistical analyses were performed using Mantel-Cox test (** $P < 0.01$).